GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Titan Pharmaceuticals Inc (FRA:TN70) » Definitions » E10

Titan Pharmaceuticals (FRA:TN70) E10 : €-667.03 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Titan Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Titan Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was €-1.141. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-667.03 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was 24.40% per year. During the past 5 years, the average E10 Growth Rate was 21.90% per year. During the past 10 years, the average E10 Growth Rate was 21.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Titan Pharmaceuticals was 30.80% per year. The lowest was 4.50% per year. And the median was 16.50% per year.

As of today (2024-06-11), Titan Pharmaceuticals's current stock price is €5.917. Titan Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 was €-667.03. Titan Pharmaceuticals's Shiller PE Ratio of today is .


Titan Pharmaceuticals E10 Historical Data

The historical data trend for Titan Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Titan Pharmaceuticals E10 Chart

Titan Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,625.74 -1,959.88 -1,215.24 -657.02 -642.47

Titan Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -786.11 -808.12 -804.10 -642.47 -667.03

Competitive Comparison of Titan Pharmaceuticals's E10

For the Biotechnology subindustry, Titan Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Titan Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Titan Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Titan Pharmaceuticals's Shiller PE Ratio falls into.



Titan Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Titan Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.141/131.7762*131.7762
=-1.141

Current CPI (Mar. 2024) = 131.7762.

Titan Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201406 -145.729 100.560 -190.968
201409 -139.681 100.428 -183.282
201412 -175.178 99.070 -233.011
201503 -798.342 99.621 -1,056.026
201506 -352.839 100.684 -461.800
201509 -288.687 100.392 -378.937
201512 -363.531 99.792 -480.044
201603 -290.955 100.470 -381.614
201606 1,762.218 101.688 2,283.634
201609 -384.915 101.861 -497.959
201612 -511.787 101.863 -662.081
201703 -538.565 102.862 -689.953
201706 -544.684 103.349 -694.504
201709 -604.085 104.136 -764.427
201712 -532.765 104.011 -674.983
201803 -360.087 105.290 -450.671
201806 -128.401 106.317 -159.149
201809 -349.659 106.507 -432.618
201812 -142.047 105.998 -176.592
201903 -180.542 107.251 -221.828
201906 -201.782 108.070 -246.046
201909 -98.065 108.329 -119.290
201912 -37.090 108.420 -45.080
202003 -36.743 108.902 -44.461
202006 -25.930 108.767 -31.415
202009 -25.810 109.815 -30.972
202012 -7.104 109.897 -8.518
202103 -4.704 111.754 -5.547
202106 -2.822 114.631 -3.244
202109 -3.230 115.734 -3.678
202112 -4.602 117.630 -5.155
202203 -4.358 121.301 -4.734
202206 -3.406 125.017 -3.590
202209 -3.636 125.227 -3.826
202212 -3.200 125.222 -3.367
202303 -2.083 127.348 -2.155
202306 -2.031 128.729 -2.079
202309 -0.375 129.860 -0.381
202312 -2.393 129.419 -2.437
202403 -1.141 131.776 -1.141

Add all the adjusted EPS together and divide 10 will get our e10.


Titan Pharmaceuticals  (FRA:TN70) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Titan Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Titan Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Titan Pharmaceuticals (FRA:TN70) Business Description

Traded in Other Exchanges
Address
400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080
Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.

Titan Pharmaceuticals (FRA:TN70) Headlines

No Headlines